« Previous
Next »
Titles
- Benefit-risk assessment for new drug and biological products: guidance for industry1
- CDC generally met its inspection goals for the federal select agent program: however, opportunities exist to strengthen oversight1
- Climate change: information on potential economic effects could help guide federal efforts to reduce fiscal exposure : report to Congressional requesters1
- Fundamentals of underwriting in the nongroup health insurance market: access to coverage and options for reform1
- Identification and care of those at highest risk of cancer1
- Medicare and Medicaid: CMS needs to fully align its antifraud efforts with the fraud risk framework : report to Congressional addressees1
- Medicare's use of risk adjustment1
- Veterans' health care: limited progress made to address concerns that led to high-risk designation : testimony before the Committee on Veterans' Affairs, U.S. Senate1